Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment "

NCT02530424 is registered in ClinicalTrials.gov with Fondazione Michelangelo as lead sponsor.

NCT NCT02530424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02530424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment "
Lead sponsor
Fondazione Michelangelo
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
November 30, 2019
Enrollment
102 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms